158 related articles for article (PubMed ID: 22241465)
1. The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.
Sheehan NL; van Heeswijk RP; Foster BC; Akhtar H; Singhal N; Seguin I; DelBalso L; Bourbeau M; Chauhan BM; Boulassel MR; Burger DM; Lalonde RG; Cameron DW
Molecules; 2012 Jan; 17(1):688-702. PubMed ID: 22241465
[TBL] [Abstract][Full Text] [Related]
2. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
Hirt D; Mentré F; Tran A; Rey E; Auleley S; Salmon D; Duval X; Tréluyer JM;
Br J Clin Pharmacol; 2008 Apr; 65(4):548-57. PubMed ID: 17922881
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
Panhard X; Goujard C; Legrand M; Taburet AM; Diquet B; Mentré F;
Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971
[TBL] [Abstract][Full Text] [Related]
6. Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
Bergshoeff AS; Wolfs TF; Geelen SP; Burger DM
Ann Pharmacother; 2003 Apr; 37(4):521-5. PubMed ID: 12659608
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.
Read JS; Best BM; Stek AM; Hu C; Capparelli EV; Holland DT; Burchett SK; Smith ME; Sheeran EC; Shearer WT; Febo I; Mirochnick M
HIV Med; 2008 Nov; 9(10):875-82. PubMed ID: 18795962
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.
van Heeswijk RP; Khaliq Y; Gallicano KD; Bourbeau M; Seguin I; Phillips EJ; Cameron DW
Clin Pharmacol Ther; 2004 Dec; 76(6):588-97. PubMed ID: 15592330
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Litalien C; Faye A; Compagnucci A; Giaquinto C; Harper L; Gibb DM; Jacqz-Aigrain E;
Pediatr Infect Dis J; 2003 Jan; 22(1):48-55. PubMed ID: 12544409
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
Regazzi M; Maserati R; Villani P; Cusato M; Zucchi P; Briganti E; Roda R; Sacchelli L; Gatti F; Delle Foglie P; Nardini G; Fabris P; Mori F; Castelli P; Testa L
Antimicrob Agents Chemother; 2005 Feb; 49(2):643-9. PubMed ID: 15673746
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite.
Damle BD; Uderman H; Biswas P; Crownover P; Lin C; Glue P
Br J Clin Pharmacol; 2009 Nov; 68(5):682-9. PubMed ID: 19916992
[TBL] [Abstract][Full Text] [Related]
12. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
Fang AF; Damle BD; LaBadie RR; Crownover PH; Hewlett D; Glue PW
Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
[TBL] [Abstract][Full Text] [Related]
13. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
[TBL] [Abstract][Full Text] [Related]
14. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
Kruse G; Esser S; Stocker H; Breske A; Koerber A; Kopperman M; Wiehler H; Ross B; Möcklinghoff C; Hill A; Becker M; Kurowski M
Antivir Ther; 2005; 10(2):349-55. PubMed ID: 15865230
[TBL] [Abstract][Full Text] [Related]
15. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
Khaliq Y; Gallicano K; Seguin I; Fyke K; Carignan G; Bulman D; Badley A; Cameron DW
Br J Clin Pharmacol; 2000 Aug; 50(2):108-15. PubMed ID: 10930962
[TBL] [Abstract][Full Text] [Related]
16. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Payen S; Faye A; Compagnucci A; Giaquinto C; Gibbs D; Gomeni R; Bressolle F; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2005 Feb; 49(2):525-35. PubMed ID: 15673728
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
Hirt D; Treluyer JM; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Urien S
Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569
[TBL] [Abstract][Full Text] [Related]
18. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
Stocker H; Herzmann C; Breske A; Kruse G; Berger M; Schulbin H; Hill A; Steinmüller J; Becker M; Arastéh K; Kurowski M
J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.
Bryson YJ; Mirochnick M; Stek A; Mofenson LM; Connor J; Capparelli E; Watts DH; Huang S; Hughes MD; Kaiser K; Purdue L; Asfaw Y; Keller M; Smith E;
HIV Clin Trials; 2008; 9(2):115-25. PubMed ID: 18474496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
